Haemophilia gene therapy: From trailblazer to gamechanger

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia Vol. 24; no. S6; pp. 50 - 59
• Main Authors: Evens, H., Chuah, M. K., VandenDriessche, T.
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.05.2018
• Subjects: adeno‐associated viral vectors; Animals; Clinical trials; Clotting; coagulation; CRISPR; factor IX; Factor IX - genetics; factor IX Padua; factor VIII; Factor VIII - genetics; FIX gene; Gene therapy; Gene transfer; Genetic Therapy - methods; Genetic Vectors - genetics; haemophilia; Hemophilia; Hemophilia A - genetics; Hemophilia A - therapy; Humans; Immune response; Immunosuppression; Inflammation; Insertional mutagenesis; lentiviral; Liver; Lymphocytes T; Nuclease; Toxicity; Transgenes; Vectors (Biology); zinc finger nuclease; Zinc finger proteins; CRISPR; factor IX; adeno-associated viral vectors; haemophilia; factor IX Padua; zinc finger nuclease; lentiviral; coagulation; factor VIII
• ISSN: 1351-8216; 1365-2516
• DOI: 10.1111/hae.13494

Haemophilia is an attractive disease target for gene therapy that fostered the development of the field at large. The delivery of the clotting factor genes into the patients’ cells could be accomplished using different types of gene delivery vehicles or vectors. Adeno‐associated viral vectors (AAV) and lentiviral vectors represent some of the most promising gene delivery technologies that allow for a relatively efficient delivery of the therapeutic FVIII and FIX transgenes into the relevant target cells. To reduce the risks associated with insertional mutagenesis due to random vector integration, gene‐editing approaches have also been considered based primarily on zinc finger nuclease (ZFN) and CRISPR/Cas. However, comprehensive analysis of off‐target effects is still required. It is particularly encouraging that relatively stable therapeutic FVIII or FIX expression levels were reached in severe haemophilia patients in recent clinical trials after liver‐directed AAV gene therapy. This success could be ascribed in part to improvements in vector design. In particular, clotting factor levels could be increased by codon optimization of coagulation factor transgenes. Alternatively, incorporation of a hyperactive gain‐of‐function R338L mutation (FIX Padua) in the FIX gene improved the overall efficacy. However, some patients still show transient liver toxicity, especially at high vector doses, possibly due to inflammatory immune responses, requiring the need for transient immunosuppression. The exact immune mechanisms are not fully understood, but may at least in some patients involve an AAV‐capsid specific T cell response. Moreover, there is a need to identify the key factors that contribute to the interpatient variability in therapeutic efficacy and safety after gene therapy.